Avita Medical Announces First Patient Enrolment in US Pivotal Study of ReCell® for the Treatment of Burns
Northridge, CA and Cambridge, UK, 28 January 2015. Link here. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the first patient has been enrolled in the Company’s Pivotal Phase III burn trial for ReCell®. The FDA-approved study is designed to confirm the safety and […]
